New Insights on the Diagnosis and Treatment of Nonproliferative Diabetic Retinopathy

PROGRAM CHAIR

David Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
St. Petersburg, FL

PROGRAM OVERVIEW

This enduring program targets critical issues in nonproliferative diabetic retinopathy (NPDR), including risk for retinopathy development and progression, how early treatment can help prevent progression to vision-threatening complications, and treatment strategies for NPDR. Learn essential elements of assessment and management, as well as clinical trial data on the latest approaches in care, helping to preserve vision in diabetes.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, and other healthcare providers who manage patients with nonproliferative diabetic retinopathy.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

• Determine which patients are at risk for the development and progression of NPDR
• Evaluate recent clinical data on established and emerging diagnostic and therapeutic strategies for NPDR
• Identify patients with NPDR who could benefit from the early initiation of anti-VEGF therapy

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with nonproliferative diabetic retinopathy.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

David Eichenbaum, MD, FAAO discloses the following:

• Consulting fees: Genentech, Regeneron, Allergan, Novartis, Alimera, Opthea, US Retina, EyePoint, Gyroscope, Kodiak, Recens Medical, DORC, Iveric Bio, Apellis, KKR, Regenxbio, B+L, vial, and Coherus
• Speakers’ bureau: Genentech, Bayer, Allergan, Novartis, EyePoint, Appelis, and Bausch & Lomb
• Contracted research: AsclepiX, Genentech, Regeneron, Bayer, Novartis, Opthea, Ocular Therapeutix, EyePoint, Chengdu, Gemini, Gyroscope, Kodiak, NGM, Recens Medical, Alkahest, Ionis, Iveric Bio, Regenxbio, Unity, and Annexon
• Ownership interests: Clearside Biomedical, Hemera Biopharmaceuticals, Boston Image Reading Center, Network Eye, and Outlook Therapeutics

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
• Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
• Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures
2. Participate in the enduring activity
3. Complete pre-and-post surveys and evaluation

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy‐policy/.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.